Active substanceZoledronic acidZoledronic acid
Similar drugsTo uncover
  • Aklasta
    solution in / in 
    Novartis Pharma AG     Switzerland
  • Blazter®
    lyophilizate in / in 
  • Veroclast
    lyophilizate in / in 
    VEROPHARM SA     Russia
  • Veroclast
    concentrate in / in 
    VEROPHARM SA     Russia
  • Zoledronate-Teva
    concentrate in / in 
  • Zoledronic acid
    concentrate d / infusion 
    MIR-FARM, LLC     Russia
  • Zolendronic-Rus 4
    lyophilizate in / in d / infusion 
    MANAS MED, LTD     Russia
  • Zolerix
    concentrate in / in d / infusion 
    BIOCAD, CJSC     Russia
  • Zometa®
    concentrate in / in d / infusion 
    Novartis Pharma AG     Switzerland
  • Zometa®
    solution in / in d / infusion 
    Novartis Pharma AG     Switzerland
  • Resoclastin FS
    concentrate in / in d / infusion 
    F-SYNTHESIS, CJSC     Russia
  • Resorba
    lyophilizate in / in d / infusion 
  • Resozcan, 99mTc
    lyophilizate in / in 
  • Dosage form: & nbspConcentrate for the preparation of solution for infusion.
    Composition:

    1 bottle contains: active substance zoledronic acid monohydrate (in terms of anhydrous substance) 4.00 mg; Excipients: mannitol 220.00 mg, sodium citrate 27.35 mg, hydrochloric acid q.s., sodium hydroxide q.s., water for injection up to 5,00 ml.

    Description:A clear, colorless solution.
    Pharmacotherapeutic group:Bone resorption inhibitor - bisphosphonate.
    ATX: & nbsp

    M.05.B.A.08   Zoledronic acid

    Pharmacodynamics:

    Zoledronic acid refers to bisphosphonates having a selective effect on bone tissue. Suppresses excessive resorption of bone tissue, affecting osteoclasts. The exact mechanism providing inhibition of osteoclasts activity has not yet been elucidated. Zoledronic acid does not adversely affect the formation, mineralization and mechanical properties of the bone.

    In patients with hypercalcemia, induced by malignant tumors, a single infusion of zoledronic acid is accompanied by a decrease in the concentration of calcium and phosphorus in the blood serum and an increase in the excretion of calcium and phosphorus in the urine.

    The main pathophysiological mechanism for the development of hypercalcemia in malignant neoplasms and bone metastases is the hyperactivity of osteoclasts, leading to an increase in bone resorption. Excessive release of calcium into the blood due to bone resorption leads to polyuria and gastrointestinal disorders (GI tract), accompanied by progressive dehydration and a decrease in the glomerular filtration rate,which in turn leads to an increase in the reverse absorption of calcium in the kidneys, further exacerbates systemic hypercalcemia and creates a "vicious vicious circle." Suppression of excessive resorption of bone tissue and ensuring adequate fluid intake are necessary conditions in the treatment of hypercalcemia caused by malignant neoplasm.

    According to the pathophysiological mechanism of hypercalcemia, patients with hypercalcemia caused by malignant neoplasm can be divided into two groups: patients with humoral hypercalcemia, and patients with hypercalcemia due to tumor invasion into bone tissue. In the case of humoral hypercalcemia, the activation of osteoclasts and stimulation of bone resorption is effected by factors such as parathyroid hormone-related protein, produced by tumor cells and entering the systemic circulation. Humoral hypercalcemia, as a rule, develops in squamous cell malignancies of the lungs, head and neck or tumors of the genitourinary system, such as renal cell carcinoma or ovarian cancer.In these patients, bone metastases may be absent or minimal.

    With the widespread invasion of tumor cells into bone tissue, they produce locally acting substances that activate osteoclastic bone resorption, which also leads to the development of hypercalcemia. To tumors, accompanied by locally-mediated hypercalcemia, usually include breast cancer and multiple myeloma.

    The total serum calcium concentration of patients with hypercalcemia caused by malignant neoplasm may not reflect the severity of hypercalcemia due to the presence of concomitant hypoalbuminemia. Ideally, to diagnose and treat hypercalcemic conditions, it is necessary to determine the concentration of ionized calcium, however, in many clinical situations this study is not available or is not performed quickly enough. In this regard, instead of determining the ionized calcium, a common indicator of serum calcium concentration adjusted for the level of albumin (corrected serum calcium) is often used. To carry out these calculations, there are several nomograms.

    Pharmacokinetics:

    Pharmacokinetic parameters do not depend on the dose. After the onset of infusion, the concentration in the blood plasma increases rapidly, reaching Cmax at the end of the infusion, followed by a rapid decrease in concentration by 10% after 4 hours and at less than 1% of Cmax after 24 hours with a further long period of low concentrations not exceeding 0.1% of Cmax, until repeated infusion for 28 days. The connection with plasma proteins is 56%. Not exposed to metabolism. It is excreted by the kidneys unchanged in 3 stages: 1 and 2 phases - rapid removal of zoledronic acid from the systemic blood flow with half-life (T1/2) 0.24 h and 1.87 h respectively, and the 3 rd phase - a prolonged excretion with T1/2 146 h. There was no cumulation of the drug with repeated injections every 28 days. During the first 24 hours in urine, 23-55% is found. The rest of the zoledronic acid binds to the bone tissue, after which it is slowly released back into the systemic circulation and excreted by the kidneys; with feces less than 3% is output. The total plasma clearance is 2.54-7.54 l / h, it does not depend on the dose of zoledronic acid, sex, age, race and body weight of the patient. An increase in the duration of infusion from 5 to 15 min leads to a decrease in the concentration of zoledronic acid by 30% at the endinfusion, but does not affect the area under the concentration-time curve (AUC). Kidney clearance is positively correlated with creatinine clearance (CC) and is 42-108% of CC, averaging 55-113%. In patients with severe (CC less than 20 ml / min) and moderate renal failure (QC 20 to 50 ml / min), the zoledronic acid clearance is 37% and 72%, respectively, of the zoledronic acid clearance values ​​in patients with a CC of 84 ml / min.

    Indications:

    Hypercalcemia (KSK concentration not less than 12 mg / dl or 3 mmol / l), induced by malignant tumors.

    Metastatic bone damage in malignant solid tumors and myeloma (to reduce the risk of pathological fractures, spinal cord compression, tumor-induced hypercalcemia, and reduced need for radiotherapy).

    Contraindications:

    Hypersensitivity to zoledronic acid, other bisphosphonates and other components of the drug; severe renal failure (CC less than 30 mg / min); renal failure (creatinine concentration greater than 3 mg / dL or 265 μmol / L) in patients with metastatic bone lesions in malignantsolid tumors and myeloma; renal failure (creatinine concentration greater than 4.5 mg / dL or 400 μmol / L); hepatic insufficiency in patients with hypercalcemia induced by malignant tumors; aspirin-sensitive asthma; heart disease accompanied by heart failure; hypocalcemia, children under 18 years of age (no data on efficacy and safety); pregnancy, lactation.

    Carefully:

    Caution should be exercised when using zoledronic acid in patients with bronchial asthma sensitive to acetylsalicylic acid (with the use of other bisphosphonates, there have been cases of bronchospasm, see the section "Method of administration and dose").

    Dosing and Administration:

    In the form of intravenous (IV) infusion for at least 15 minutes.

    Hypercalcemia (KSK concentration of at least 12 mg / dL or 3 mmol / L), induced by malignant tumors

    The feasibility of zoledronic acid should be determined taking into account both the severity level and the manifestations of hypercalcemia associated with malignant tumors. For the treatment of mild asymptomatic forms of hypercalcemia, there may beit is sufficient only for enhanced hydration by the introduction of saline solutions (with or without the use of loop diuretics).

    The maximum recommended dose: 4 mg in the form of a single intravenous infusion for at least 15 minutes. The introduction of a repeat dose is possible if the calcium concentration is not normalized or there is a deterioration after a distinct clinical effect. To realize the full clinical effect of the initial dose, the interval before reintroduction should be at least 7 days.

    Throughout the course of treatment, adequate hydration (saline solutions) is necessary, but excessive hydration, especially in patients with heart failure, should be avoided. It is recommended to maintain a diuresis of about 2 liters / day throughout the treatment. Diuretics can only be used after correction of hypovolemia.

    Metastatic bone damage in malignant solid tumors and myeloma

    The recommended dose in combination with standard antitumor therapy: 4 mg in the form of a single IV infusion for at least 15 minutes every 3-4 weeks.

    To prevent hypocalcemia and preserve homeostasis, patients should also take calcium preparations at a dose of 500 mg / day and multivitamins, containing vitamin D, at a rate of 400 IU / day in combination with standard antitumor therapy.

    Patients with renal insufficiency

    The introduction of zoledronic acid leads to an increased risk of developing nephrotoxic syndrome. In patients with hypercalcemia with an initial moderate impairment of renal function (creatinine concentration not more than 4.5 mg / dL), dose adjustment is not required. If signs of worsening kidney function appear, an appropriate examination should be performed to determine the relationship between the potential benefit of further treatment and the possible risk. In patients with a creatinine concentration of more than 4.5 mg / dL (400 μmol / L) zoledronic acid It is applied only in case of prevalence of expected benefit over possible risk of development of renal failure.

    In patients with renal insufficiency in the treatment of metastatic bone lesions in malignant solid tumors and myeloma, the dose is adjusted according to the indices of renal dysfunction:

    • it is not recommended to administer zoledronic acid to patients who have a creatinine concentration of more than 3 mg / dl:
    • with CC above 60 ml / min, the recommended dose of the drug is 4.0 mg (5.0 ml concentrate);
    • at CC from 50 to 60 ml / min the recommended dose of the preparation is 3.5 mg (4.4 ml of concentrate);
    • with SC from 40 to 49 ml / min the recommended dose of the drug is 3.3 mg (4.1 ml of concentrate);
    • with QC from 30 to 39 ml / min the recommended dose of the drug is 3.0 mg (3.8 ml of concentrate);
    • with QC less than 30 ml / min, zoledronic acid is not used.

    Patients who showed progressive renal dysfunction during treatment were resumed after a decrease in serum creatinine levels to within 10% of the baseline.

    Patients with hepatic insufficiency

    The experience of using zoledronic acid in the treatment of hypercalcemia induced by malignant tumors in patients with hepatic insufficiency is limited, and the data obtained do not allow us to recommend a certain dosing regimen or tactics of safe use in such patients.

    Application for asthma

    Patients with aspirin-sensitive asthma have had cases of bronchial obstruction with other bisphosphonates. Despite the lack of data on such manifestations on the background of treatment with zoledronic acid,caution should be exercised when prescribing to patients with aspirin-sensitive asthma.

    Preparation of a solution for infusions

    Before the administration of the preparation, concentrate (the contents of one vial or a smaller volume) is diluted in 100 ml of an infusion solution that does not contain calcium (0.9% sodium chloride solution or 5% dextrose solution).

    Do not mix Zoledronate-Teva with other medications, solutions containing calcium or other divalent cations, including Ringer's lactate solution. The prepared zoledronic acid solution must be administered using a separate system for intravenous infusion immediately after preparation.

    Side effects:

    Side effects of zoledronic acid are usually minor and transient, similar to side effects noted with the use of other bisphosphonates. In / in infusion is often accompanied by a fever. Often, patients develop an influenza-like syndrome, including fever, chills, fever, bone pain and / or arthralgia, myalgia. After IV introduction, reactions from the digestive tract, such as nausea and vomiting, are noted.Local reactions at the site of administration, such as redness or swelling, are less than in 1% of patients. In most cases, the symptoms disappear within 24-48 hours without specific treatment.

    It has been reported rare cases of skin rash, itching and chest pain after the administration of zoledronic acid.

    Just as with the use of other bisphosphonates, cases of conjunctivitis and hypomagnesemia have been reported.

    The incidence of adverse reactions is classified according to WHO recommendations: very often - not less than 10%; often - not less than 1%, but less than 10%; infrequently - not less than 0,1%, but less than 1%; rarely - not less than 0.01%, but less than 0.1%; very rarely - less than 0.01% (including single cases or at an unset frequency).

    On the part of the digestive system: often - nausea, vomiting; infrequently - abdominal pain, constipation, diarrhea; frequency is not established - stomatitis, dryness of the oral mucosa, dyspepsia, inflammation of the gastrointestinal mucosa.

    From the side of the blood and lymphatic system: often - anemia; infrequently - thrombocytopenia; rarely - pancytopenia; frequency is not established - granulocytopenia, neutropenia.

    From the laboratory indicators: very often - hypophosphatemia; often - hypocalcemia; infrequently - hypokalemia, hypomagnesemia.

    From the side of metabolism: dehydration, anorexia, increased sweating.

    From the musculoskeletal system: arthralgia, muscle cramps, asthenia, bone pain, muscle pain, back pain, pain in the limbs.

    From the nervous system: often - headache, confusion; infrequently - dizziness, hypoesthesia, hyperesthesia, paresthesia; frequency not established - anxiety, nervousness, anxiety, irritability, sleep disturbance, depression, hallucinations, drowsiness, dizziness, taste perversion, insomnia, tremor, anxiety.

    From the cardiovascular system: infrequently - arterial hypotension; rarely - aetiology.

    From the respiratory system: infrequently - shortness of breath, cough; frequency is not established - a pleural effusion, a pain in a thorax.

    From the skin: frequency not established - alopecia.

    Allergic reactions: infrequently - itchy skin; frequency is not established - dermatitis, angioedema.

    From the genitourinary system: often - renal dysfunction; infrequently - hematuria, proteinuria.

    From the musculoskeletal system: often - pain in the joints, pain in the bones of myalgia; frequency is not established - pain in the back area, pain in the chest.

    On the part of the organs of vision: often - conjunctivitis; infrequently - blurred vision; very rarely - episcleritis, uveitis.

    Benign, malignant and unspecified neoplasms (including cysts and polyps): frequency is not established - complication of the course and progression of malignant formation.

    Infectious diseases: frequency is not established - candidiasis, infectious diseases of the upper respiratory tract, infectious diseases of the urinary tract.

    Other: often - the flu-like syndrome; infrequently - asthenia; frequency is not established - peripheral edemas, hyperthermia, fast fatigue.

    Overdose:

    Symptoms: In acute drug overdose (limited data), renal dysfunction (including renal failure), changes in electrolyte composition (including calcium, phosphate and magnesium concentrations in blood plasma) were noted. The patient who received the drug in a dose exceeding the recommended dose should be under constant supervision.

    Treatment: when hypocalcemia, hypophosphatemia or hypomagnesemia with clinically significant manifestations is shown, the infusion of gluconate calcium, sodium or potassium phosphate, magnesium sulfate, respectively.

    Interaction:

    With the simultaneous use of other commonly used medications (antitumor agents, antibiotics, analgesics) with zoledronic acid, no clinically significant interactions were noted.

    According to data obtained in in vitro studies, zoledronic acid has no significant binding to plasma proteins and does not inhibit the isoenzymes of the cytochrome P450 system. Special clinical studies on the study of drug interactions were not conducted.

    It is advisable to use caution when using bisphosphonates and aminoglycosides at the same time, since the simultaneous action of these drugs is manifested by an increase in the duration of the decrease in the concentration of calcium in the blood plasma. With caution apply the drug with loop diuretics in connection with an increased risk of hypercalcemia. Caution is also needed when using zoledronic acid with drugs potentially having a nephrotoxic effect.

    It should also be borne in mind the likelihood of hypomagnesemia.

    In patients with multiple myeloma, there may be an increased risk of developing renal dysfunction with IV infusionbisphosphonates, including zoledronic acid, in combination with thalidomide.

    Pharmaceutical interaction

    The diluted zoledronic acid solution should not be mixed with infusion solutions containing calcium ions (for example, Ringer's lactate solution).

    When using glass bottles, infusion systems and bags of different types made of polyvinyl chloride, polyethylene and polypropylene (previously filled with 0.9% sodium chloride solution or 5% dextrose solution), no signs of incompatibility with zoledronic acid were detected.

    Special instructions:

    Before the beginning of treatment and throughout the course of treatment, it is necessary to correct the symptoms of dehydration and hypovolemia. It is recommended to maintain a diuresis of about 2 liters / day throughout the course of treatment.

    After the start of therapy, careful monitoring of the concentration of calcium, phosphorus and magnesium in blood serum is necessary. Zoledronic acid It is not used in patients with initial hypocalcemia. Violation of the electrolyte balance (hypocalcemia, hypomagnesemia or hypophosphatemia) requires short-term replenishment therapy.

    Before each dose is administered, a determination of the creatinine concentration to determine the function of the kidneys is necessary.

    The condition of patients receiving zoledronic acid for the treatment of hypercalcaemia in malignant tumors with confirmed progressive renal dysfunction should be appropriately evaluated to determine the prevalence of the expected benefit of continuous treatment over a possible risk. In connection with the possibility of clinically significant impairment of kidney function up to renal failure, a single dose should not exceed 4 mg and the duration of infusion should be at least 15 minutes.

    Avoid excessive hydration in patients with heart failure. There are reports of cases of osteonecrosis of the jaw in patients with a cancer tumor, whose regimens have included bisphosphonates. Many of these patients also received chemotherapy and corticosteroids. Most of the reports relate to patients who underwent dental procedures, such as tooth extraction, while there were signs of local infection, including osteomyelitis.

    Patients with a history of such risk factors as cancer tumors, chemotherapy, corticosteroids, problems with oral hygiene, it is recommended that the bisphosphonates be inspected and sanitized before starting treatment with bisphosphonates. During treatment with bisphosphonates, these patients, if possible, should avoid traumatic dental procedures, because bisphosphonates presumably create conditions for the onset of osteonecrosis of the jaw. There are no reports of a decrease in the risk of osteonecrosis of the jaw with a decrease in the dose of bisphosphonates or discontinuation of bisphosphonate therapy in patients who need to perform dental procedures. The clinical scheme of the patient's treatment in this situation is determined by the attending physician and is based on an individual benefit / risk ratio estimate.

    Effect on the ability to drive transp. cf. and fur:

    The study of the effect of zoledronic acid on the ability to drive vehicles and working mechanisms was not carried out. However, care should be taken when developing side effects from the nervous system (dizziness, drowsiness), which can cause a decrease in concentration and psychomotor reactions.

    Form release / dosage:

    Concentrate for the preparation of a solution for infusions of 4 mg / 5 ml.

    Packaging:

    By 5 ml of the drug in vials of transparent plastic with stoppers made of bromobutyl rubber and aluminum caps equipped with a protective cap made of polypropylene; 1 bottle, placed in a transparent pallet of PVC, or 1 bottle without a pallet along with instructions for use in a cardboard bundle.

    Storage conditions:

    At a temperature not exceeding 30 ° C.

    Keep out of the reach of children.
    Shelf life:

    2 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-001001
    Date of registration:18.10.2011
    The owner of the registration certificate:Teva Pharmaceutical Enterprises Co., Ltd.Teva Pharmaceutical Enterprises Co., Ltd. Israel
    Manufacturer: & nbsp
    Representation: & nbspTeva Teva Israel
    Information update date: & nbsp04.09.2015
    Illustrated instructions
      Instructions
      Up